SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

HC Wainwright Maintains Buy Rating on LENZ Therapeutics, Cuts Target to $16

HC Wainwright cut its price target on LENZ Therapeutics to $16 per share from $38, while maintaining its Buy rating.

LENZ

Related stories